Mylan NV (MYL)

37.38
0.55 1.50
NASDAQ : Health Care
Prev Close 36.83
Open 37.25
Day Low/High 37.14 / 37.47
52 Wk Low/High 37.59 / 67.34
Volume 1.73M
Avg Volume 5.84M
Exchange NASDAQ
Shares Outstanding 535.50M
Market Cap 19.86B
EPS 1.80
P/E Ratio 40.30
Div & Yield N.A. (N.A)

Latest News

Bank Earnings Are at a Critical Turning Point: Cramer's 'Mad Money' Recap (Wednesday 4/12/17)

Bank Earnings Are at a Critical Turning Point: Cramer's 'Mad Money' Recap (Wednesday 4/12/17)

Loss of bank leadership and the recent pullback are major factors in what's ailing the markets, says Jim Cramer.

Mylan Falls on FDA Warning on Quality Control

Mylan Falls on FDA Warning on Quality Control

The EpiPen-maker has received a letter from the FDA about its manufacturing facility in Nashik, India.

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Mylan Expands EpiPen Recall

Mylan Expands EpiPen Recall

The company fell nearly 2% after announcing the news this weekend.

FDA Rejection of Mylan Generic Adds to its Woes

FDA Rejection of Mylan Generic Adds to its Woes

The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

The company could be gearing up for multiple challenges on the D.C. front, analysts say.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.

Can This Pharma Stock Withstand the 'Trump Effect'?

Can This Pharma Stock Withstand the 'Trump Effect'?

With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?

Mylan Hit After Abbott Dumps Shares

Mylan Hit After Abbott Dumps Shares

The company decreased its 13% stake in Mylan Friday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan CEO Heather Bresch's father sponsored a bill that made it easier for generic drugs to be substituted back in 1986. This helped Mylan become the largest generic manufacturer.

Mylan Receives Tentative Approval For

Mylan Receives Tentative Approval For "TLE400" Under PEPFAR

- TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

The settlement provides Mylan with global licenses for its trastuzumab product.

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

A firestorm in Washington has created a fire sale for shares of this undervalued stock.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?